QBREXZA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for QBREXZA (QBREXZA).
Selective D1 and D5 dopamine receptor antagonist; reduces dopamine-mediated vasodilation in choroidal blood vessels, decreasing choroidal thickness and neovascularization.
| Metabolism | Primarily metabolized by CYP3A4 and CYP2D6; minor contributions from CYP1A2 and CYP2C19. |
| Excretion | Renal: approximately 30% as unchanged drug; fecal: approximately 60% as metabolites and parent compound; biliary excretion contributes to fecal elimination. |
| Half-life | Terminal elimination half-life is approximately 150 hours (range 120-200 hours), supporting once-daily dosing without significant accumulation. |
| Protein binding | Approximately 99% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 17 L (not weight-adjusted; clinical meaning: drug distributes into total body water and tissues, with extensive protein binding limiting free drug concentration). |
| Bioavailability | Topical: systemic absorption is low (approximately 0.2% of applied dose), with negligible bioavailability after topical application. |
| Onset of Action | Topical: reduction in sweating observed within 1-2 weeks of daily application. |
| Duration of Action | Duration of effect persists for 24 hours with once-daily application; continued use required to maintain efficacy. |
| Molecular Weight | 406.47 |
1 capsule (40 mg) orally twice daily with or without food.
| Dosage form | CLOTH |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (eGFR <30 mL/min/1.73 m²) or ESRD; use caution. |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not recommended in moderate to severe hepatic impairment (Child-Pugh B or C). |
| Pediatric use | Safety and efficacy in pediatric patients (<18 years) have not been established. |
| Geriatric use | No specific dose adjustment; however, elderly patients may have increased sensitivity to anticholinergic effects. Use with caution in patients >65 years due to potential comorbidities and concomitant medications. |
| 1st trimester | Insufficient human data; based on animal studies, may cause fetal harm. Avoid use unless benefit outweighs risk. |
| 2nd trimester | Insufficient human data; based on animal studies, may cause fetal harm. Avoid use unless benefit outweighs risk. |
| 3rd trimester | Insufficient human data; based on animal studies, may cause fetal harm. Avoid use unless benefit outweighs risk. |
Clinical note
Comprehensive clinical and safety monograph for QBREXZA (QBREXZA).
| Placental transfer | Based on molecular weight (<500 Da), expected to cross placenta; animal studies show placental transfer. |
| Breastfeeding | No data on presence in human milk; potential for serious adverse reactions in nursing infants. Decision should consider importance of drug to mother and potential risks. Alternatively, consider discontinuing breastfeeding or drug. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to QBREXZA or any component of the formulation
| Precautions | Risk of retinal artery occlusion and retinal vein occlusion, May cause increased intraocular pressure (IOP); monitor IOP regularly, Potential for cardiovascular events (hypotension, bradycardia) due to systemic exposure, Avoid use in patients with uncontrolled hypertension or recent cardiovascular events, Potential for drug interactions with CYP3A4 and CYP2D6 inhibitors/inducers |
| Food/Dietary | Avoid high-fat meals before taking QBREXZA as they can reduce absorption. Grapefruit and grapefruit juice should be avoided as they may increase glycopyrrolate levels. Maintain adequate hydration but avoid excessive fluid intake with meals to prevent dilution of drug effect. |
Loading safety data…
| Lactation Rating | L4 |
| Teratogenic Risk | Insufficient human data; animal studies show no teratogenic effects at systemic exposures similar to human therapeutic levels, but risk cannot be excluded; first trimester: theoretical risk; second/third trimester: no known specific fetal risks. |
| Fetal Monitoring | No specific fetal monitoring required; monitor maternal blood pressure and signs of angioedema. |
| Fertility Effects | No human data on fertility; animal studies show no impairment at clinically relevant doses. |
| Clinical Pearls | QBREXZA (glycopyrrolate) is an anticholinergic agent used for severe sialorrhea. Onset is ~1 week; max effect by 4-6 weeks. Avoid in patients with glaucoma, urinary retention, or GI obstruction. Use with caution in elderly due to anticholinergic side effects. Monitor for constipation, blurred vision, and urinary hesitancy. |
| Patient Advice | Take exact dose as prescribed to avoid dry mouth and other side effects. · Do not chew or crush tablets; swallow whole. · Avoid alcohol and CNS depressants as they may increase drowsiness. · Report difficulty urinating, blurred vision, or severe constipation to your doctor. · May cause heat stroke in hot environments due to decreased sweating. |